Hazlin John reported option exercise involving 23,376 derivative units of COLGATE PALMOLIVE CO at $0.00 for $0 on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Growth Officer
Chief Growth Officer
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
23,376Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 6, 2026, 4:04 PM ET2-day reporting delay
Accession
0001225208-26-008751Code M · Transaction 394603
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Option exercise23,376$77.04$1,800,887.04Trade 394601
Nov 4, 2026Sell23,376$99.15−$2,317,681.31Trade 394602
3 transaction rows in this filing. Joint filers share the same rows.

CL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −11%1w ago −5%1d ago −1.3%
Returns since7d +3.2%30d90d180d1y

Footnotes in full

F1: Exercise of stock options awarded under the issuer's incentive compensation plan. F2: Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3: Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.93 to $99.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2021 grant date.